Business Context and Reporting Period
Company: Butterfly Network, Inc. (BFLY)
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Quarter and nine months ended September 30, 2024
Business Overview: Butterfly Network is a digital health company providing portable, semiconductor-based ultrasound technology (Butterfly iQ+ and iQ3) paired with cloud-connected software. The company operates as a single reportable segment and has incurred net losses since inception.
Key Financial Metrics
| Metric (in thousands) | Q3 2024 | Q3 2023 | 9M 2024 | 9M 2023 |
|---|---|---|---|---|
| Total Revenue | $20,561 | $15,421 | $59,705 | $49,384 |
| Gross Profit | $12,233 | $9,382 | $35,096 | $29,393 |
| Gross Margin | 59.5% | 60.8% | 58.8% | 59.5% |
| Net Loss | $(16,924) | $(27,368) | $(54,391) | $(89,579) |
| Diluted EPS | $(0.08) | $(0.13) | $(0.26) | $(0.44) |
| Cash and Equivalents (End of Period) | $93,758 | $150,006 | $93,758 | $150,006 |
| Net Cash Used in Operating Activities | N/A | N/A | $(38,587) | $(85,719) |
Note: Cash and equivalents figures represent the balance as of September 30, 2024, and December 31, 2023, respectively, as quarterly cash flow totals are not explicitly provided in the text for the three-month period.
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 33.3% year-over-year (YoY) in Q3 2024, driven primarily by a 54.7% increase in product revenue. Product revenue growth was fueled by higher sales of the iQ3 probe (which has a higher selling price) and international distributor volume, which quadrupled YoY.
- Expense Reductions: Operating expenses decreased significantly due to prior-year workforce reductions.
- R&D: Decreased 27.1% in Q3 2024 ($8.8M vs $12.1M) and 34.8% for the nine months.
- General & Administrative: Decreased 19.1% in Q3 2024 ($9.4M vs $11.6M) and 19.8% for the nine months.
- Other Expenses: Decreased 81.9% in Q3 2024 ($1.7M vs $9.2M) due to lower legal costs and severance payments compared to the prior year.
- Profitability: While the company remains unprofitable, the net loss narrowed significantly. Q3 2024 net loss was $16.9M compared to $27.4M in Q3 2023. The nine-month net loss was $54.4M compared to $89.6M in the prior year.
- Liquidity: Cash and cash equivalents decreased from $134.4M at year-end 2023 to $93.8M at September 30, 2024. Net cash used in operating activities for the nine months ended September 30, 2024, was $38.6M, a 55% improvement over the $85.7M used in the prior year period.
Guidance, Outlook, and Risks
- Cash Runway: Management expects current cash of $93.8 million to be sufficient to fund operations for at least the next 12 months. The company conservatively expects cash to last into 2027 following cost reduction initiatives that lowered annual cash requirements to less than $50 million.
- Future Capital Needs: The company anticipates needing to raise capital before 2027 to reach profitability. It plans to prioritize non-dilutive capital (licensing, grants, debt) before considering equity securities.
- Revenue Mix: Due to the launch of the iQ3 device, management expects the software and services mix as a percentage of total revenue to remain flat or decrease in 2024, despite long-term goals to shift toward higher-margin software revenue.
- Key Risks:
- Litigation: The company is defending against a putative class action lawsuit (Rose v. Butterfly Network, Inc.) and two stockholder derivative actions regarding financial disclosures and internal controls. Outcomes are uncertain, and insurance adequacy is not guaranteed.
- Regulatory & Market: Risks include obtaining/maintaining regulatory approvals, competition from larger firms, and reimbursement challenges for medical procedures.
- Supply Chain: The company has $8.6 million in minimum inventory purchase commitments, with $1.8 million in vendor advances.
Investor Verification Checklist
- Cash Burn Rate: Verify the sustainability of the $93.8M cash balance against the projected $50M annual cash requirement and the timeline for potential capital raises.
- Revenue Quality: Assess the sustainability of the 54.7% product revenue growth, specifically the contribution of the higher-priced iQ3 probe versus volume growth.
- Software Mix Trend: Monitor the "Software and other services mix" metric, which decreased to 34.2% in Q3 2024, to ensure it does not negatively impact long-term margin expansion goals.
- Litigation Exposure: Review the status of the Rose class action and derivative suits to evaluate potential financial impact beyond the accrued legal expenses.
- Inventory Commitments: Confirm the company's ability to fulfill $8.6M in inventory purchase commitments without incurring significant excess and obsolete (E&O) charges.